SURUNKALI BUYRAK KASALLIGIDA β2-MIKROGLOBULINNING DIAGNOSTIK VA PROGNOSTIK AHAMIYATI
Kalit so'zlar
https://doi.org/10.47390/3030-3133V3I2Y2025N02Kalit so'zlar
β₂-mikroglobulin, surunkali buyrak kasalligi, erta markerlar, uremik toksinlar, SBK rivojlanishiAnnotasiya
Ushbu tadqiqotda surunkali buyrak kasalligining (SBK) I-III bosqichlaridagi bemorlarning qon zardobidagi β₂-mikroglobulin miqdori oʻrganildi. Jinsi va yoshi boʻyicha mos keladigan 68 nafar bemor va 20 nafar amalda sogʻlom shaxs tekshirildi. β₂-mikroglobulin darajasi immunoferment usuli bilan aniqlandi. Olingan natijalar SBKning dastlabki bosqichlaridayoq β₂-mikroglobulin miqdorining sezilarli darajada oshganini va keyinchalik glomerulyar filtratsiya tezligi pasayishi bilan bu koʻrsatkich yanada ortib borganini koʻrsatdi. β₂-mikroglobulin miqdorining koʻpayishi ham kanalchalar disfunksiyasini, ham uremik toksikozning kuchayib borayotganini aks ettirishi mumkin. Ushbu maʼlumotlar β₂-mikroglobulinning SBK rivojlanishining erta belgilaridan biri sifatidagi prognostik ahamiyatini taʼkidlaydi.
Manbalar
1. Авганбекова Г.М., Турсунова Л.Д., Жаббаров О.О. ЗАВИСИМОСТЬ АНГИОГРАФИЧЕСКИХ ХАРАКТЕРИСТИК ПОРАЖЕНИЙ КОРОНАРНЫХ АРТЕРИЙ ОТ ФАКТОРОВ РИСКА СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ У БОЛЬНЫХ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ //SCHOLAR. – 2025. – Т. 3. – №. 1. – С. 108-115.
2. Жаббаров О. О., Турсунова Л. Д., Хужаниязова Н. К. ВНУТРИПОЧЕЧНАЯ ГЕМОДИНАМИКА ПРИ ДИАБЕТИЧЕСКОЙ НЕФРОПАТИИ //Академические исследования в современной науке. – 2024. – Т. 3. – №. 44. – С. 114-115.
3. Мирзаева, Ш. X., et al. "Сурункали буйрак касаллиги бўлган беморларда кардиоренал синдромни даволаш." (2022).
4. Bataille R., Klein B. The role of beta 2-microglobulin in multiple myeloma. Blood. 1986;68(3):583–586.
5. Bernard A.M. Clinical significance of urinary proteins in nephrology. Clin Nephrol. 1989;32(1):42–46.
6. Cohen G., Haag-Weber M., Hörl W.H. Immune dysfunction in uremia. Kidney Int Suppl. 1997;62:S79–S82.
7. Cummings J, et al. (2018). "Use of β2-microglobulin in the evaluation of chronic kidney disease." Nephrology Review, 16(2), 22-28.
8. Eckardt K.U., Coresh J., Devuyst O., et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382(9887):158–169.
9. Erlandsen E.J., Randers E., Kristensen J.H. Reference intervals for serum beta2-microglobulin and cystatin C in adults. Clin Chem Lab Med. 1998;36(11):905–909
10. Filler G., Priem F., Lepage N., et al. β2-Microglobulin in renal disease. Clin Biochem. 2001;34(4):237–247.
11. Garcia-Garcia, G., et al. (2017). "Prognostic value of β2-microglobulin for end-stage renal disease." Nephrology, 22(8), 675-683.
12. Han WK, et al. (2002). "Urinary biomarkers for early detection of acute kidney injury." Kidney International, 62(4), 1205-1212.
13. Hsu C.Y., Chertow G.M. β2-Microglobulin predicts mortality in chronic kidney disease. Clin Nephrol. 2006;66(4):235–241.
14. Jabbarov O. O. Disorders Function of the Heart and Kidney in Diabetes Mellitus. – 2023.
15. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1–150.
16. Kao, C.-Y., et al. (2019). "Correlation of β2-microglobulin and cystatin C in kidney function assessment." Kidney International, 56(5), 2085-2092.
17. Lee S, et al. (2019). "β2-microglobulin as a prognostic marker in chronic kidney disease." Clinical Journal of the American Society of Nephrology, 14(9), 1301-1308.
18. Levey AS, et al. (2007). "Chronic kidney disease: basic principles and clinical practice." The Lancet, 370(9582), 939-953.
19. Levin A., Stevens P.E. Summary of KDIGO 2012 CKD Guideline: A clinical practice approach. Kidney Int. 2014;85(5):879–883.
20. Liu Y, et al. (2020). "β2-microglobulin in chronic kidney disease: Its role in diagnosis and prognosis." Clinical Nephrology, 93(3), 137-144.
21. Maduell F, et al. (2018). "β2-microglobulin as a diagnostic marker for chronic kidney disease." Nephrology Dialysis Transplantation, 33(4), 701-707.
22. Matsushita K., van der Velde M., Astor B.C., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality. Lancet. 2010;375(9731):2073–2081.
23. O'Neill WC, et al. (2015). "β2-microglobulin: A key marker for kidney disease in diabetes." Diabetes Care, 38(6), 1105-1112.
24. Schardijn G.H., Statius van Eps L.W. Beta2-microglobulin: its significance in the evaluation of renal function. Kidney Int. 1987;32(5):635–641.
25. Shinkai S., Chaves P.H., Fujiwara Y., et al. β2-Microglobulin and mortality among older adults in the community. Clin Exp Nephrol. 2006;10(4):282–288.
26. Thomas R, et al. (2018). "Limitations of creatinine in the diagnosis of kidney disease." Nephrology and Dialysis Transplantation, 33(4), 707-715.
27. Tursunova L. D., Jabbarov O. O. APPLICATION OF SAKABUTRIL/VALSARTAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH TYPE 2 DIABETES MELLITUS //Art of Medicine. International Medical Scientific Journal. – 2021. – Т. 1. – №. 1.
28. Tursunova L., Jabbarov O. O. THE ROLE OF RENAL VASCULAR DOPPLEROGRAPHY IN THE DIAGNOSIS OF CHRONIC KIDNEY DISEASE //Медицинский журнал молодых ученых. – 2024. – №. 12 (12). – С. 52-57.
29. Wong J.Y., Lee S., Choi M.J. Serum and urinary beta-2 microglobulin levels in chronic kidney disease. Korean J Intern Med. 2015;30(3):476–484.
30. Erlandsen E.J., Randers E., Kristensen J.H. Reference intervals for serum beta2-microglobulin and cystatin C in adults. Clin Chem Lab Med. 1998;36(11):905–909
